Cover Image
市场调查报告书

生物模拟技术的全球市场

Biosimulation Technology

出版商 Global Industry Analysts, Inc. 商品编码 341978
出版日期 内容信息 英文 164 Pages
商品交期: 最快1-2个工作天内
价格
Back to Top
生物模拟技术的全球市场 Biosimulation Technology
出版日期: 2015年09月01日 内容信息: 英文 164 Pages
简介

本报告涵括生物模拟技术的全球市场,提供您美国,加拿大,日本,欧洲,亚太地区,南美,及其他地区等各地区之个别分析,2013年~2020年各年的实际成果/估计及预测,再汇整42家主要企业及利基企业之公司简介。

第1章 简介,调查方法,产品定义

  • 调查的可靠性和报告的限制
  • 免责声明
  • 数据的解释和报告水准
    • 定量技术及分析法
  • 产品的定义和调查范围

第2章 摘要整理

  • 产业概要
    • 生物模拟:是药物研究开发上一大优点
    • 现在及未来分析
    • 应用领域和终端用户领域
    • 生物模拟提供药物开发的模式转移
    • 主要市场发展推动因素概要
    • 市场发展阻碍因素
    • 竞争
  • 市场发展推动因素
    • 医疗费的增加促进药物研发及药物开发需求
    • CDD的发生数量及盛行率的增加:主要的发展推动因素
    • 全世界人口的高龄化促使先进性药物的研究开发
    • 传统药物研发相关高成本
    • 临床试验后期的高失败率
    • 最近临床试验后期的失败案例清单 (2014年)
    • 中国与印度:研究开发投资的热点
    • 生物模拟克服了小儿科开发药剂中课题
  • 市场趋势‐考察
    • 模拟工具可去除扩大中的生命科学研究开发预算的压力
    • 生物模拟突破了神经退化性疾病的瓶颈
    • 显示出糖尿病研究的新道路
    • 生物模拟从开发支持转移到临床工具
    • 肺生物模拟:为OIP开发带来变革
    • 药物重新配置的生物模拟
    • 电网型对接支持生物模拟
    • 更优秀模式的需求:促使市场上创新的主要原因
  • 技术概要
    • 生物模拟:简单的介绍
    • 药物研发和药物开发
    • 药物开发过程的各阶段
    • 药物开发技术
    • 人生理学
    • 数学的模式和生物模拟技术
    • Bottom-Up(由下而上)建模
    • Top-Down(由上而下)建模
  • 产品的发表/认证
  • 最新产业趋势
  • 主要的国际企业
  • 全球市场的展望

第3章 市场

  • 美国
  • 加拿大
  • 日本
  • 欧洲
    • 法国
    • 德国
    • 义大利
    • 英国
    • 西班牙
    • 俄罗斯
    • 其他欧洲
  • 亚太地区
  • 南美
  • 其他地区

第4章 竞争情形

目录
Product Code: MCP-7920

This report analyzes the worldwide markets for Biosimulation Technology in US$ Thousand. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 42 companies including many key and niche players such as -

Advanced Chemistry Development, Inc.
Biovia
Certara L.P
Chemical Computing Group
Entelos, Inc.

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

  • Study Reliability and Reporting Limitations
  • Disclaimers
  • Data Interpretation & Reporting Level
    • Quantitative Techniques & Analytics
  • Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW

  • Biosimulation: Massively Benefiting Drug R&D
  • Current and Future Analysis
  • Application and End-user Areas
    • Table 1: Global Biosimulation Market by Application (2014): Percentage Share of Revenue in Drug Development, Drug Discovery, and Others (includes corresponding Graph/Chart)
    • Table 2: Global Biosimulation Market by End-user Sector (2014): Percentage Share of Revenue for Academic Research Institutes, Biotechnology/Drug Companies, Contract Research Organizations (CROs), Regulatory Organizations, and Others (includes corresponding Graph/Chart)
  • Biosimulation Offers Paradigm Shift in Drug Development
  • Key Market Drivers in a Nutshell
  • Market Restraints
  • Competition

2. GROWTH DRIVERS

  • Increasing Healthcare Expenditure Drives the Need for Drug Discovery and Development
    • Table 3: Per Capita Healthcare Expenditure in US$ by Select Country (includes corresponding Graph/Chart)
    • Table 4: Healthcare Expenditure as % of GDP by Select Country (includes corresponding Graph/Chart)
  • Increasing Incidence and Prevalence of CDDs: A Major Growth Driver
    • Table 5: Worldwide Incidence of Cancer in Million: 2012, 2020 & 2030 (includes corresponding Graph/Chart)
    • Table 6: Global Annual Medical Cost of CVD in US$ Billion (2010-2030) (includes corresponding Graph/Chart)
  • Aging Global Population Drives Advanced Drug R&D
    • Table 7: Global Population Statistics for the 65+ Age Group (2012) (includes corresponding Graph/Chart)
    • Table 8: Elderly Population (65+ Years) as a % of Total Population (2000 & 2025) (includes corresponding Graph/Chart)
  • High Costs Associated with Traditional Drug Discovery
    • Table 9: Escalating Costs of New Drug Development Over the Decades (includes corresponding Graph/Chart)
    • Table 10: US R&D Productivity Trends in Pharma Industry (2006- 2013) (includes corresponding Graph/Chart)
  • High Failure Rate of Late-Stage Drug Trials
  • List of Recent Late-stage Drug Failures (2014)
  • China and India: Hot Spots for R&D Investment
    • Table 11: Percentage Breakup of Global R&D Spending by Region (2012) (includes corresponding Graph/Chart)
  • Biosimulation Overcomes Challenges in Pediatric Drug Development

3. MARKET TRENDS - AN INSIGHT

  • Simulation Tools Take the Pressure off Mounting Life Science R&D Budgets
    • Table 12: Global Life Science R&D Expenditure (2011-2014): Total R&D Spending in US$ Billion (includes corresponding Graph/Chart)
  • Biosimulation Gets Neurodegenerative Disease Out of the Cul-de-sac
  • Marking New Avenues in Diabetes Research
  • Biosimulation Moving From Discovery Aid to Clinical Tool
  • Lung Biosimulation: Game Changer for OIP Development
  • Biosimulation for Drug Repositioning
  • Grid-based Docking Aids Biosimulation
  • Need for Better Models: A Major Factor Driving Innovation in the Market

4. TECHNOLOGY OVERVIEW

  • Biosimulation - A Brief Introduction
  • Drug Discovery and Development
  • Stages in Drug Development Process
    • Target identification
    • Target Validation
    • Lead Identification
    • Lead Optimization
    • Pre-Clinical Testing
    • Clinical Trials
  • Drug Discovery Technologies
  • Human Physiology
  • Mathematical Models and Biosimulation Technique
  • Bottom-up Modeling
  • Top-Down Modeling

5. PRODUCT LAUNCHES/APPROVALS

  • Certara Launches Simcyp In Vitro Analysis Toolkit Version 1.0
  • Optimata Granted US Patent for Biosimulation Technology
  • Cognigen Releases Version 1.3 of KIWI™
  • Simulations Plus Releases Version 9.0 of GastroPlus™
  • Certara Launches Version 2.0 of Cardiac Safety Simulator
  • Certara Releases Version 14 of Simcyp™ Simulator
  • Certara Receives FDA Grant for MechDermA
  • Physiomics Launches EasyAP™
  • Rhenovia Pharma Develops Simulator for Epilepsy Mechanisms
  • Insilico Biotechnology Launches Simulation Platform for Virtual Organs

6. RECENT INDUSTRY ACTIVITY

  • Certara Merges Its Pharsight Consulting with Quantitative Solutions
  • Optivia Biotechnology and Rhenovia Pharma Sign Partnership Agreement
  • Physiomics Signs Contract with Merck Serono
  • PMDA Equips Pharmacometrics Team with Certara's Biosimulation Solutions
  • CQDM and Alsace-Biovalley Collaborate on Biosimulation Platform
  • Dassault Systemes Acquires Accelrys
  • Rhenovia Pharma Secures Series B Funding
  • Pharmacelsus and Insilico Biotechnology Collaborate for Preclinical Drug Analysis
  • Arsenal Capital Partners Acquires Certara
  • Entelos Enters Into Licensing Agreement with USFDA

7. FOCUS ON SELECT GLOBAL PLAYERS

  • Advanced Chemistry Development, Inc. (Canada)
  • Biovia (Formerly Accelrys) (US)
  • Certara L.P. (US)
  • Chemical Computing Group (Canada)
  • Entelos, Inc. (US)
  • In Silico Biosciences, Inc. (US)
  • InhibOx (UK)
  • Insilico Biotechnology AG (Germany)
  • LeadInvent Technologies (India)
  • Leadscope, Inc. (US)
  • Nimbus Therapeutics (US)
  • OpenEye Scientific Software Inc. (US)
  • Physiomics Plc. (UK)
  • Rhenovia Pharma SAS (France)
  • Schrodinger, LLC (US)
  • Simulations Plus, Inc.(US)

8. GLOBAL MARKET PERSPECTIVE

    • Table 13: World Recent Past, Current & Future Analysis for Biosimulation Technology by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 14: World 8-Year Perspective for Biosimulation Technology by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets for Years 2013, 2015 & 2020 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

  • A. Market Analysis
    • Biosimulation to Abate Life Sciences R&D Spending
    • Table 15: The US Life Science Industry Annual R&D Expenditure: 2011-2014 (includes corresponding Graph/Chart)
    • Ageing Population - Booster for Effective Drug Development
    • Table 16: North American Elderly Population by Age Group: 1975-2050 (includes corresponding Graph/Chart)
    • Rise in Chronic Disorders Drive Market Growth
    • Table 17: US Diabetics Population (2010-2017): Percentage Population with Diagnosed and Undiagnosed Diabetes (includes corresponding Graph/Chart)
    • Table 18: High Blood Pressure Prevalence in the US (2012): Prevalence Rates for Male and Female Population by Age Groups (includes corresponding Graph/Chart)
    • Table 19: High Blood Pressure Prevalence in the US (2012): Prevalence Rates for Male and Female Population by Ethnic Group (includes corresponding Graph/Chart)
    • Table 20: New Cancer Cases in the US by Gender and Affected Site: 2014E (includes corresponding Graph/Chart)
    • Product Launches
    • Strategic Corporate Developments
    • Key Players
  • B. Market Analytics
    • Table 21: The US Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

2. CANADA

  • A. Market Analysis
    • Increasing Incidence of Cancer: A Major Growth Driver
    • Table 22: New Cancer Cases in Canada by Gender and Affected Site: 2014E (includes corresponding Graph/Chart)
    • Strategic Corporate Development
    • Key Players
  • B. Market Analytics
    • Table 23: Canadian Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

3. JAPAN

  • A. Market Analysis
    • Graying Population Spurs Demand for Advanced Drug Development
    • Table 24: Japanese Elderly (65+ Years) Population: 2000-2020 (includes corresponding Graph/Chart)
    • Strategic Corporate Development
  • B. Market Analytics
    • Table 25: Japanese Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

4. EUROPE

  • A. Market Analysis
    • Regulatory Authorities Stress on Paradigm Shift in Drug Development
    • Ageing Population Boosts Demand
    • Table 26: European Country-wise Statistics of 60+ Population as % of Total Population: 2013 (includes corresponding Graph/Chart)
  • B. Market Analytics
    • Table 27: European Recent Past, Current & Future Analysis for Biosimulation Technology by Geographic Region - France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 28: European 8-Year Perspective for Biosimulation Technology by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets for Years 2013, 2015 & 2020 (includes corresponding Graph/Chart)

4a. FRANCE

  • A. Market Analysis
    • Strategic Corporate Developments
    • Rhenovia Pharma SAS - A Key Player
  • B. Market Analytics
    • Table 29: French Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

4b. GERMANY

  • A. Market Analysis
    • Product Launch
    • Strategic Corporate Development
    • Insilico Biotechnology AG - A Key Player
  • B. Market Analytics
    • Table 30: German Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

4c. ITALY

  • Market Analysis
    • Table 31: Italian Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

4d. UNITED KINGDOM

  • A. Market Analysis
    • Product Launch
    • Strategic Corporate Development
    • Key Players
  • B. Market Analytics
    • Table 32: The UK Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

4e. SPAIN

  • Market Analysis
    • Table 33: Spanish Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

4f. RUSSIA

  • Market Analysis
    • Table 34: Russian Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

4g. REST OF EUROPE

  • Market Analysis
    • Table 35: Rest of European Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC

  • A. Market Analysis
    • Growing Population and Aging Demographic Drive Demand for Advanced Drug Development
    • Table 36: Population Statistics in Asia (Including Japan) & Percentage of Population Aged Above 65 Years (includes corresponding Graph/Chart)
    • Leadinvent Technologies (India) - A Key Player
  • B. Market Analytics
    • Table 37: Asia-Pacific Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

6. LATIN AMERICA

  • Market Analysis
    • Table 38: Latin American Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

7. REST OF WORLD

  • A. Market Analysis
    • Product Launch
  • B. Market Analytics
    • Table 39: Rest of World Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Back to Top